Mounce574 wrote: ↑August 4th, 2024, 7:44 pm
Adaboo wrote: ↑June 12th, 2024, 4:29 am
To me, they can only refuse it when they are not infected by the virus. If they are infected, they should take it. And many people have different perspectives on why vaccines can be potentially harmful to the human system. True?
The vaccine wouldn't work if the person already has the disease. This is a fact.
Since I work with animals, I am not certain if humans could do something like thi:. At the clinic, we would run blood "titers" that would tell whether the animal has a sufficient amount of antibodies against diseases that have vaccines in them. An average dog, if it has gotten its normal vaccines at 8 weeks, 16 weeks, 6 months, and a year (on schedule) generally will not need to have another vaccine for the rest of its life. Every time you inject a disease (live or dead) into your body, it causes your immune system to react- compromising its ability to fight as effectively until it has destroyed/neutralized that disease.
Antibody titers are an important aspect of human healthcare, as they are frequently used to determine the quantity of certain antibodies in the blood. These tests are used for a variety of objectives, including identifying whether someone has obtained immunity to certain diseases after vaccination, analyzing the efficacy of a vaccine, and diagnosing whether an individual has previously been exposed to a specific pathogen. For example, after receiving the Hepatitis B vaccine, healthcare workers or those at high risk of infection should (ideally) have their antibody levels checked to ensure they have adequate immunity. Similarly, antibody titers can be used for diseases like measles, mumps, and rubella (MMR) or varicella (chickenpox) to verify immunity, especially in instances when vaccination history is uncertain or when confirming immunity before potential exposure.
However, there were a number of reasons why using antibody titers broadly during the COVID-19 pandemic was not feasible. First, because the unique SARS-CoV-2 virus that gave COVID-19 was unknown at first, it was difficult to determine what antibody levels would be necessary to provide adequate protection. This was in sharp contrast to recognized diseases, for which immunity thresholds had long been identified. Moreover, it would have been extremely difficult to coordinate the logistics of testing antibody titers on billions of individuals either before or after vaccination. Vaccinating as many people as possible as soon as possible was the main goal during a worldwide pandemic, not postponing the process with extensive antibody testing.
Another important issue was the introduction of new varieties of the virus. As SARS-CoV-2 changed, new variants made existing antibodies less effective, making it difficult to create a consistent antibody titer threshold that could be used to assess immunity. Furthermore, the immune response to COVID-19 is complicated, comprising not only antibodies but also T-cell-mediated immunity, which is difficult to quantify and complicates the use of antibody titers as a definitive measure of protection.
These difficulties explain why, despite their usefulness in certain situations, antibody titer tests were not the go-to option during the global COVID-19 problem.